Trial Information
Summary: Investigational Oral Medication for RRMS
The goal of this study is to determine if an investigational oral medication is safe and effective. This treatment with the investigational oral medication is compared to treatment with a placebo. A placebo is an inactive substance or preparation used as a control in an experiment or test to determine the effectiveness of a medicinal drug. If you qualify, your participation may last up to two years and will require approximately 26 visits to the research office. Throughout that time, medical professionals with expertise in Multiple Sclerosis (MS) are available to monitor you closely.
If you are between the ages of 18 and 55, and have a confirmed diagnosis of Relapsing-Remitting Multiple Sclerosis (RRMS) with at least one relapse in the past 12 months, you may qualify for this study.
If you have never been treated with Copaxone (glatiramer acetate), you may also qualify for a related study, CONFIRM. CONFIRM is evaluating an oral treatment for RRMS.
If you would like more information on this study, or to Pre-Screen Yourself, visit http://www.msclinicalstudies.com
Contact Information:
Research Centers
Located in:
Dayton, OH
Bellevue, OH
Cleveland, OH
Email: ms@dandersoncompany.com
Thanks for posting this information. I am new to your site and I will have to come back to read more. You have a lot here to read.
http://www.healthcentral.com/multiple-sclerosis/c/73302/profile
By: Meander on August 31, 2008
at 3:35 pm